等待開盤 10-27 09:30:00 美东时间
+0.090
+1.55%
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.
10-20 23:57
Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of
10-20 16:08
Company plans to focus its portfolio on North America and Japan CHICAGO, Oct. 17, 2025 /PRNewswire/ -- Grainger (NYSE: GWW), a leading broad line supplier of maintenance, repair and operatin...
10-17 18:00
A Brand Inspired By Sofia's Instinctive Style And An Expansion Of REVOLVE's In-House Brand Portfolio LOS ANGELES, Oct. 16, 2025 /PRNewswire/ -- Revolve Group, Inc. (NYSE: RVLV), the next-ge...
10-17 00:00
Rain City Resources ( ($TSE:RAIN) ) has shared an update. The Saskatchewan gove...
10-07 02:35
An announcement from Rain City Resources ( ($TSE:RAIN) ) is now available. Rain...
10-03 02:07
6 analysts have shared their evaluations of Impinj (NASDAQ:PI) during the recen...
09-15 21:00
Shares of machine companies are trading higher amid overall market strength. St...
09-12 03:48
The Impact Awards Recognize Purpose-Driven Customers Using Blackbaud Software to Fuel Impact CHARLESTON, S.C., Sept. 10, 2025 /PRNewswire/ -- Blackbaud (NASDAQ: BLKB), the leader in AI for s...
09-10 23:00
(来源:市场投研资讯) 摘要 本周观点 本周,我们梳理了PD-(L)1/VEGF作用机制、在研产品以及催化剂。 关注PD-(L)1/VEGF赛道,202...
09-01 14:59